CAPPED BONUS CERTIFICATE - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 07:55:20 20/06/2024 BST | ||
| 92.75 EUR | 0.00% |
|
| Current month | +0.69% | ||
| 1 month | +1.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 92.75 | 0.00% |
| 19/06/24 | 92.75 | +0.39% |
| 18/06/24 | 92.39 | -0.32% |
| 17/06/24 | 92.69 | +0.08% |
| 14/06/24 | 92.62 | +0.17% |
Real-time Boerse Frankfurt Warrants
Last update June 20, 2024 at 07:55 am
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW93GF |
| ISIN | DE000SW93GF2 |
| Date issued | 08/05/2024 |
| Strike | 950 kr |
| Maturity | 20/12/2024 (184 Days) |
| Parity | 10 : 1 |
| Emission price | 91.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 93 € |
|---|---|
| Lowest since issue | 90.58 € |
| Spread | 0.47 € |
| Spread % | 0.50% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984.2
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.07%
- Stock Market
- Certificates
- Certificat
